The tumor exosome profiling market size has grown rapidly in recent years. It will grow from $1.13 billion in 2025 to $1.32 billion in 2026 at a compound annual growth rate (CAGR) of 16.9%. The growth in the historic period can be attributed to growing cancer prevalence, advances in molecular biology techniques, increasing adoption of liquid biopsy methods, rising research funding for oncology, demand for non-invasive diagnostic tools.
The tumor exosome profiling market size is expected to see rapid growth in the next few years. It will grow to $2.49 billion in 2030 at a compound annual growth rate (CAGR) of 17.1%. The growth in the forecast period can be attributed to integration of ai and bioinformatics in exosome profiling, development of personalized medicine solutions, expansion of diagnostic laboratories, adoption of high-throughput exosome analysis platforms, growth in cancer biomarker discovery. Major trends in the forecast period include liquid biopsy integration, high-throughput exosome analysis, automated sample preparation, multi-omics data profiling, personalized cancer therapeutics.
The increasing prevalence of cancer is anticipated to drive the growth of the tumor exosome profiling market in the coming years. Cancer encompasses a group of diseases characterized by uncontrolled proliferation and division of abnormal cells, which can invade nearby tissues and metastasize to other body regions. The rise in cancer prevalence is attributed to unhealthy lifestyles, including poor nutrition, physical inactivity, smoking, and excessive alcohol consumption, all of which elevate the risk of various cancer types. Tumor exosome profiling aids cancer management by enabling early detection, monitoring tumor progression, and guiding personalized therapy through analysis of tumor-derived exosomes in body fluids. For instance, in February 2024, according to the World Health Organization, a Switzerland-based international organization specializing in global health policy and public health initiatives, over 35 million new cancer cases are projected in 2050, representing a 77% increase from the estimated 20 million cases in 2022. Therefore, the increasing prevalence of cancer is propelling rapid growth in the tumor exosome profiling market.
Key companies operating in the tumor exosome profiling market are focusing on developing innovative solutions, such as liquid biopsy-based exosome assays, to enable early cancer detection and personalized therapy monitoring. A liquid biopsy-based exosome assay is a blood test that detects tiny vesicles called exosomes released by tumor cells, allowing doctors to identify and monitor cancer without invasive tissue biopsies. For example, in June 2024, Mercy BioAnalytics Inc., a US-based biotechnology company, partnered with University College London (UCL), a UK-based university, to launch the Mercy Halo Ovarian Cancer Screening Test, a next-generation extracellular vesicle liquid biopsy designed to identify ovarian cancer in asymptomatic, postmenopausal women by detecting multiple co-localized cancer biomarkers on individual tumor-derived vesicles using a low-volume blood sample and quantitative polymerase chain reaction (qPCR)-based readout, offering high sensitivity and specificity several years before clinical diagnosis.
In September 2025, MDxHealth SA, a Belgium-based healthcare technology company, acquired Exosome Diagnostics, Inc. from Bio Techne Corporation for $15 million. With this acquisition, MDxHealth seeks to expand its liquid-based diagnostic offerings and reinforce its leadership in prostate cancer diagnostics by integrating ExoDx prostate cancer testing and associated clinical laboratory assets. Exosome Diagnostics Inc. is a US-based healthcare technology company that specializes in comprehensive, proprietary tumor exosome profiling and liquid biopsy services.
Major companies operating in the tumor exosome profiling market are Thermo Fisher Scientific Inc., Lonza Group Ltd., NanoFCM Inc., QIAGEN N.V., Bio-Techne Corporation, Miltenyi Biotec B.V. And Co. KG, Aethlon Medical Inc., Cusabio Technology LLC, Norgen Biotek Corp., Kimera Labs Inc, Diagenode Inc., Creative Biolabs Inc, Izon Science Ltd., System Biosciences LLC, Mercy Bioanalytics Inc, MtoZ Biolab, Capital Biosciences Inc., ExoCan Healthcare Technologies Private Limited, INOVIQ Ltd, Codiak BioSciences Inc.
North America was the largest region in the tumor exosome profiling market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tumor exosome profiling market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the tumor exosome profiling market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The tumor exosome profiling market consists of revenues earned by entities by providing services such as exosome isolation and purification, next-generation sequencing (ngs) services, custom exosome research services, exosome biomarker discovery and validation, and exosome-based liquid biopsy services. The market value includes the value of related goods sold by the service provider or included within the service offering. The tumor exosome profiling market also includes sales of exosome analysis and characterization instruments, bioinformatics software and analytics tools, affinity based isolation columns and spin column kits, high throughput microfluidic platforms, and exosome biomarker profiling libraries and reagents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Tumor exosome profiling involves the analysis and characterization of exosomes, which are small extracellular vesicles released by tumor cells containing molecular information such as proteins, RNA, and DNA. This profiling provides insights into tumor biology, helps identify biomarkers, and supports the development of diagnostic or therapeutic strategies for cancer management.
The key product types of tumor exosome profiling include kits and reagents, instruments, software, and services. Kits and reagents isolate, detect, and analyze exosomes from biological samples, enabling accurate disease diagnostics and research. Sample types include blood, urine, saliva, and others. Applications include cancer diagnostics, prognostics, therapeutics, and research, serving hospitals, clinics, research institutes, diagnostic laboratories, and other end users.
Tariffs have influenced the tumor exosome profiling market by raising the cost of importing specialized instruments, kits, and reagents required for profiling. This has primarily impacted segments such as instruments and kits, especially in regions like North America and Europe that rely heavily on imports for advanced laboratory equipment. However, tariffs are encouraging local manufacturing and innovation, driving the development of cost-efficient, domestically produced solutions and fostering market resilience.
The tumor exosome profiling market research report is one of a series of new reports that provides tumor exosome profiling market statistics, including tumor exosome profiling industry global market size, regional shares, competitors with a tumor exosome profiling market share, detailed tumor exosome profiling market segments, market trends and opportunities, and any further data you may need to thrive in the tumor exosome profiling industry. This tumor exosome profiling market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
This product will be delivered within 1-3 business days.
The tumor exosome profiling market size is expected to see rapid growth in the next few years. It will grow to $2.49 billion in 2030 at a compound annual growth rate (CAGR) of 17.1%. The growth in the forecast period can be attributed to integration of ai and bioinformatics in exosome profiling, development of personalized medicine solutions, expansion of diagnostic laboratories, adoption of high-throughput exosome analysis platforms, growth in cancer biomarker discovery. Major trends in the forecast period include liquid biopsy integration, high-throughput exosome analysis, automated sample preparation, multi-omics data profiling, personalized cancer therapeutics.
The increasing prevalence of cancer is anticipated to drive the growth of the tumor exosome profiling market in the coming years. Cancer encompasses a group of diseases characterized by uncontrolled proliferation and division of abnormal cells, which can invade nearby tissues and metastasize to other body regions. The rise in cancer prevalence is attributed to unhealthy lifestyles, including poor nutrition, physical inactivity, smoking, and excessive alcohol consumption, all of which elevate the risk of various cancer types. Tumor exosome profiling aids cancer management by enabling early detection, monitoring tumor progression, and guiding personalized therapy through analysis of tumor-derived exosomes in body fluids. For instance, in February 2024, according to the World Health Organization, a Switzerland-based international organization specializing in global health policy and public health initiatives, over 35 million new cancer cases are projected in 2050, representing a 77% increase from the estimated 20 million cases in 2022. Therefore, the increasing prevalence of cancer is propelling rapid growth in the tumor exosome profiling market.
Key companies operating in the tumor exosome profiling market are focusing on developing innovative solutions, such as liquid biopsy-based exosome assays, to enable early cancer detection and personalized therapy monitoring. A liquid biopsy-based exosome assay is a blood test that detects tiny vesicles called exosomes released by tumor cells, allowing doctors to identify and monitor cancer without invasive tissue biopsies. For example, in June 2024, Mercy BioAnalytics Inc., a US-based biotechnology company, partnered with University College London (UCL), a UK-based university, to launch the Mercy Halo Ovarian Cancer Screening Test, a next-generation extracellular vesicle liquid biopsy designed to identify ovarian cancer in asymptomatic, postmenopausal women by detecting multiple co-localized cancer biomarkers on individual tumor-derived vesicles using a low-volume blood sample and quantitative polymerase chain reaction (qPCR)-based readout, offering high sensitivity and specificity several years before clinical diagnosis.
In September 2025, MDxHealth SA, a Belgium-based healthcare technology company, acquired Exosome Diagnostics, Inc. from Bio Techne Corporation for $15 million. With this acquisition, MDxHealth seeks to expand its liquid-based diagnostic offerings and reinforce its leadership in prostate cancer diagnostics by integrating ExoDx prostate cancer testing and associated clinical laboratory assets. Exosome Diagnostics Inc. is a US-based healthcare technology company that specializes in comprehensive, proprietary tumor exosome profiling and liquid biopsy services.
Major companies operating in the tumor exosome profiling market are Thermo Fisher Scientific Inc., Lonza Group Ltd., NanoFCM Inc., QIAGEN N.V., Bio-Techne Corporation, Miltenyi Biotec B.V. And Co. KG, Aethlon Medical Inc., Cusabio Technology LLC, Norgen Biotek Corp., Kimera Labs Inc, Diagenode Inc., Creative Biolabs Inc, Izon Science Ltd., System Biosciences LLC, Mercy Bioanalytics Inc, MtoZ Biolab, Capital Biosciences Inc., ExoCan Healthcare Technologies Private Limited, INOVIQ Ltd, Codiak BioSciences Inc.
North America was the largest region in the tumor exosome profiling market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tumor exosome profiling market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the tumor exosome profiling market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The tumor exosome profiling market consists of revenues earned by entities by providing services such as exosome isolation and purification, next-generation sequencing (ngs) services, custom exosome research services, exosome biomarker discovery and validation, and exosome-based liquid biopsy services. The market value includes the value of related goods sold by the service provider or included within the service offering. The tumor exosome profiling market also includes sales of exosome analysis and characterization instruments, bioinformatics software and analytics tools, affinity based isolation columns and spin column kits, high throughput microfluidic platforms, and exosome biomarker profiling libraries and reagents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Tumor exosome profiling involves the analysis and characterization of exosomes, which are small extracellular vesicles released by tumor cells containing molecular information such as proteins, RNA, and DNA. This profiling provides insights into tumor biology, helps identify biomarkers, and supports the development of diagnostic or therapeutic strategies for cancer management.
The key product types of tumor exosome profiling include kits and reagents, instruments, software, and services. Kits and reagents isolate, detect, and analyze exosomes from biological samples, enabling accurate disease diagnostics and research. Sample types include blood, urine, saliva, and others. Applications include cancer diagnostics, prognostics, therapeutics, and research, serving hospitals, clinics, research institutes, diagnostic laboratories, and other end users.
Tariffs have influenced the tumor exosome profiling market by raising the cost of importing specialized instruments, kits, and reagents required for profiling. This has primarily impacted segments such as instruments and kits, especially in regions like North America and Europe that rely heavily on imports for advanced laboratory equipment. However, tariffs are encouraging local manufacturing and innovation, driving the development of cost-efficient, domestically produced solutions and fostering market resilience.
The tumor exosome profiling market research report is one of a series of new reports that provides tumor exosome profiling market statistics, including tumor exosome profiling industry global market size, regional shares, competitors with a tumor exosome profiling market share, detailed tumor exosome profiling market segments, market trends and opportunities, and any further data you may need to thrive in the tumor exosome profiling industry. This tumor exosome profiling market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Tumor Exosome Profiling Market Characteristics
3. Tumor Exosome Profiling Market Supply Chain Analysis
4. Global Tumor Exosome Profiling Market Trends and Strategies
5. Tumor Exosome Profiling Market Analysis of End Use Industries
7. Global Tumor Exosome Profiling Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Tumor Exosome Profiling Total Addressable Market (TAM) Analysis for the Market
9. Tumor Exosome Profiling Market Segmentation
10. Tumor Exosome Profiling Market Regional and Country Analysis
11. Asia-Pacific Tumor Exosome Profiling Market
12. China Tumor Exosome Profiling Market
13. India Tumor Exosome Profiling Market
14. Japan Tumor Exosome Profiling Market
15. Australia Tumor Exosome Profiling Market
16. Indonesia Tumor Exosome Profiling Market
17. South Korea Tumor Exosome Profiling Market
18. Taiwan Tumor Exosome Profiling Market
19. South East Asia Tumor Exosome Profiling Market
20. Western Europe Tumor Exosome Profiling Market
21. UK Tumor Exosome Profiling Market
22. Germany Tumor Exosome Profiling Market
23. France Tumor Exosome Profiling Market
24. Italy Tumor Exosome Profiling Market
25. Spain Tumor Exosome Profiling Market
26. Eastern Europe Tumor Exosome Profiling Market
27. Russia Tumor Exosome Profiling Market
28. North America Tumor Exosome Profiling Market
29. USA Tumor Exosome Profiling Market
30. Canada Tumor Exosome Profiling Market
31. South America Tumor Exosome Profiling Market
32. Brazil Tumor Exosome Profiling Market
33. Middle East Tumor Exosome Profiling Market
34. Africa Tumor Exosome Profiling Market
36. Tumor Exosome Profiling Market Competitive Landscape and Company Profiles
37. Tumor Exosome Profiling Market Other Major and Innovative Companies
41. Tumor Exosome Profiling Market High Potential Countries, Segments and Strategies
42. Appendix
Executive Summary
Tumor Exosome Profiling Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses tumor exosome profiling market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for tumor exosome profiling? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The tumor exosome profiling market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product Type: Kits and Reagents; Instruments; Software; Services2) By Sample Type: Blood; Urine; Saliva; Other Sample Types
3) By Application: Cancer Diagnostics; Prognostics; Therapeutics; Research
4) By End-User: Hospitals and Clinics; Research Institutes; Diagnostic Laboratories; Other End-Users
Subsegments:
1) By Kits and Reagents: Isolation Kits; Detection Kits; Quantification Kits; Labeling Reagents; Antibodies2) By Instruments: Flow Cytometers; Nanoparticle Tracking Analyzers; Ultracentrifuges; Microfluidic Devices; Polymerase Chain Reaction Machines (PCR) Machines
3) By Software: Data Analysis Software; Visualization Software; Bioinformatics Platforms; Statistical Modeling Software; Exosome Tracking Software
4) By Services: Sample Preparation Services; Exosome Isolation Services; Molecular Profiling Services; Data Analysis Services; Custom Assay Development Services
Companies Mentioned: Thermo Fisher Scientific Inc.; Lonza Group Ltd.; NanoFCM Inc.; QIAGEN N.V.; Bio-Techne Corporation; Miltenyi Biotec B.V. And Co. KG; Aethlon Medical Inc.; Cusabio Technology LLC; Norgen Biotek Corp.; Kimera Labs Inc; Diagenode Inc.; Creative Biolabs Inc; Izon Science Ltd.; System Biosciences LLC; Mercy Bioanalytics Inc; MtoZ Biolab; Capital Biosciences Inc.; ExoCan Healthcare Technologies Private Limited; INOVIQ Ltd; Codiak BioSciences Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Tumor Exosome Profiling market report include:- Thermo Fisher Scientific Inc.
- Lonza Group Ltd.
- NanoFCM Inc.
- QIAGEN N.V.
- Bio-Techne Corporation
- Miltenyi Biotec B.V. And Co. KG
- Aethlon Medical Inc.
- Cusabio Technology LLC
- Norgen Biotek Corp.
- Kimera Labs Inc
- Diagenode Inc.
- Creative Biolabs Inc
- Izon Science Ltd.
- System Biosciences LLC
- Mercy Bioanalytics Inc
- MtoZ Biolab
- Capital Biosciences Inc.
- ExoCan Healthcare Technologies Private Limited
- INOVIQ Ltd
- Codiak BioSciences Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | May 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 1.32 Billion |
| Forecasted Market Value ( USD | $ 2.49 Billion |
| Compound Annual Growth Rate | 17.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
